Wednesday, Nov. 6, 2019
2 – 6:30 p.m.
Program Purpose
With the approval of the first bispecific T-cell engager in 2018, and with many more such multi-targeted antibodies in clinical trials, there has been a resurgence of interest in these multi-functional platforms. Other related platforms, such as cytokine fusions and CAR T cell approaches, are also making their mark on the cancer treatment landscape. As these agents make their way into the clinic, however, many important scientific and clinical questions have been raised. During this half-day program, multi-targeted therapeutic platforms will be discussed by experts in the field, along with the opportunity for investigators to submit their own related work for consideration at this unique symposium.
Intended Audience
The intended audience for this program includes, but is not limited to, basic, translational and clinical researchers; postdoctoral fellows; clinicians; and payers involved in cancer research from such affiliations as academia, industry and regulatory agencies.
Program Organizers
- Alessandra Cesano, MD, PhD – ESSA Pharma Inc.
- Edward Cha, MD, PhD – Genentech
- Leena Gandhi, MD, PhD – Eli Lilly
- Israel Lowy, MD, PhD – Regeneron Pharmaceuticals
- Salil Patel, PhD – Bristol-Myers Squibb
- Eric Rubin, MD – Merck & Co., Inc.
Educational Objectives
Upon completion of this meeting, participants will be able to:
- Describe the different types of multi-targeted therapeutic platforms in preclinical and clinical studies.
- Explain the similarities and differences between multi-targeted therapies and other immunotherapies in clinical use, such as adoptive cell therapies.
- Understand the current state of clinical trials and approvals in cancer that employ multi-targeted therapeutic platforms.
SITC's Program: Novel Multi-Targeted Therapeutic Platforms is supported in part by grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Gilead Sciences, Inc., Merck & Co., Inc. and Pfizer, Inc. (as of Sept. 27, 2019)
Presentation Application Submission
Applications for consideration to present during the Novel Multi-Targeted Therapeutic Platforms Pre-Conference Program were due by Aug. 1, 2019 at 5 p.m. PDT.
Submission Criteria
Application reviewers consider a number of variables in reviewing and selecting the applications for presentation, including, but not limited to, the following criteria:
- Content within your presentation application submission should be publicly available to present by Nov. 6, 2019.
Presentations should address one or more of the following topics:
- Novel multi-targeted therapeutics in development for the treatment of cancer (antibodies, cytokine fusions, CAR Ts, etc.)
- Combination therapies for the treatment of cancer that use a multi-targeted therapeutic
- Studies of mechanisms of action of multi-targeted therapeutics, as well as response/resistance to these treatments
- Investigation of other related scientific and clinical questions for multi-targeted therapeutics
Preference will be given to presentation application submissions with the following:
- Has human models and clinical data
- Has minimal overlap with other submitted presentations applications
- Has not been presented elsewhere or have significant changes to the submission since last being presented or published
Program Schedule
| 2 p.m. |
Introduction
|
Session 1: Basics of Multi-Targeted Therapeutic Platforms
|
Time:
|
2:05 – 4:15 p.m.
|
| 2:05 p.m. |
Overview of Different Platform Structures
|
| 2:25 p.m. |
Cytokine Fusions
Raphael Clynes, MD, PhD – Xencor, Inc.
|
| 2:45 p.m. |
Multi-Targeted CAR T cells
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
|
| 3:05 p.m. |
BiTEs, TriKEs, TriNKETs
Jeffrey S. Miller, MD – University of Minnesota
|
| 3:25 p.m. |
Break
|
| 3:40 p.m. |
Pros and Cons of Multi-Targeted Therapeutics Panel Discussion
Panelists:
Raphael Clynes, MD, PhD – Xencor, Inc.
David S. Hong, MD – The University of Texas MD Anderson Cancer Center
Israel Lowy, MD, PhD – Regeneron Pharmaceuticals
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
Jeffrey S. Miller, MD – University of Minnesota
|
Session 2: Novel Platforms and Innovation
|
Time:
|
4:15 – 5:15 p.m.
|
| 4:15 p.m. |
Contextual reprogramming of T cells for multi-targeted therapeutics: checkpoint blockade, immune resilience, and stemness to overcome immune resistance and reduce toxicity, all in one cell product
Francesco M. Marincola, MD – Refuge Biotechnologies
|
| 4:25 p.m. |
The first personalized adoptive cellular therapy trial using defined multiple targets (ACTolog IMA101-101)
Steffen Walter, PhD – Immatics US
|
| 4:35 p.m. |
A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism
Nicholas Keen, PhD – Bicycle Therapeutics
|
| 4:45 p.m. |
Combining CD27 costimulation and PD-1 blockade into a bispecific antibody improves T cell activation and anti-tumor activity over combination of individual antibodies
Tibor Keller, PhD – Celldex Therapetuics, Inc.
|
| 4:55 p.m. |
Development of novel multi-specific compounds for cancer immunotherapy using the DARPin® technology platform
Victor Levitsky, MD, PhD – Molecular Partners AG
|
5:05 p.m.
|
The uniqueness and persistence of clonal profiles associated with response in study C-144-01 following treatment with lifileucel (LN-144) supports using a polyclonal product to treat solid tumors
Viktoria Gontcharova, PhD – Iovance Biotherapeutics
|
5:15 p.m.
|
Break
|
Session 3: Clinical Applications of Multi-Targeted Therapeutic Platforms
|
| Time: |
5:30 - 6:25 p.m.
|
| 5:30 p.m. |
Clinical Trial Designs
R. Angelo de Claro, MD – Food and Drug Administration
|
| 5:50 p.m. |
Compare and Contrast with Cellular Therapies Panel Discussion
Panelists:
R. Angelo de Claro, MD – Food and Drug Administration
Steffen Walter, PhD – Immatics US
Victor Levitsky, MD, PhD – Molecular Partners AG
Tibor Keler, PhD – Celldex Therapetuics, Inc.
Francesco M. Marincola, MD – Refuge Biotechnologies
Nicholas Keen, PhD – Bicycle Therapeutics
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
|
| 6:25 p.m. |
Closing |